Intracerebroventricular Streptozotocin Injections as a Model of Alzheimer's Disease: in Search of a Relevant Mechanism

Molecular Neurobiology
P Grieb

Abstract

Streptozotocin (STZ), a glucosamine-nitrosourea compound derived from soil bacteria and originally developed as an anticancer agent, in 1963 has been found to induce diabetes in experimental animals. Since then, systemic application of STZ became the most frequently studied experimental model of insulin-dependent (type 1) diabetes. The compound is selectively toxic toward insulin-producing pancreatic beta cells, which is explained as the result of its cellular uptake by the low-affinity glucose transporter 2 (GLUT2) protein located in their cell membranes. STZ cytotoxicity is mainly due to DNA alkylation which results in cellular necrosis. Besides pancreatic beta cells, STZ applied systemically damages also other organs expressing GLUT2, such as kidney and liver, whereas brain is not affected directly because blood-brain barrier lacks this transporter protein. However, single or double intracerebroventricular (icv) STZ injection(s) chronically decrease cerebral glucose uptake and produce multiple other effects that resemble molecular, pathological, and behavioral features of Alzheimer's disease (AD). Taking into consideration that glucose hypometabolism is an early and persistent sign of AD and that Alzheimer's brains present f...Continue Reading

References

Jul 1, 1976·Diabetes·O P GandaA A Like
Jun 5, 1992·Brain Research·R SchechterS U Devaskar
Apr 10, 1992·Science·J A Hardy, G A Higgins
Nov 1, 1969·The Journal of Clinical Investigation·A JunodA E Renold
Sep 1, 1973·Journal of Neurochemistry·R W HortonH S Bachelard
Jan 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·B C Reed, M D Lane
Dec 1, 1994·International Journal of Developmental Neuroscience : the Official Journal of the International Society for Developmental Neuroscience·R DuelliS Hoyer
Jul 1, 1996·Journal of the Neurological Sciences·M OgawaJ Kimura
Feb 3, 1999·Journal of Neural Transmission·D MüllerS Hoyer
Mar 3, 1999·Proceedings of the National Academy of Sciences of the United States of America·M MasutaniT Sugimura
Mar 17, 1999·Proceedings of the National Academy of Sciences of the United States of America·A A PieperS H Snyder
Feb 24, 2001·Annals of the New York Academy of Sciences·S HoyerR Schliebs
Aug 2, 2001·Journal of Molecular Neuroscience : MN·Q R Smith, H Nagura
Feb 19, 2002·Kidney International·Thorsten P DegenhardtJohn W Baynes
Jul 16, 2003·Journal of Neurochemistry·María Angeles GarcíaFrancisco Nualart
Aug 20, 2003·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Daniel EinhornPeter W F Wilson
Oct 31, 2003·Journal of the American College of Surgeons·Eric R Frykberg
Feb 26, 2004·Proceedings of the National Academy of Sciences of the United States of America·Markus SchubertJens C Brüning
Jul 17, 2004·Histochemistry and Cell Biology·George L King, Mary R Loeken
May 25, 2005·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Salvatore Cuzzocrea
Jun 28, 2005·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·K SrinivasanP Ramarao
Jul 26, 2005·Biochemical and Biophysical Research Communications·Ruben SchechterKenneth E Miller
Nov 25, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Rodney A VelliquetteRobert Vassar
Dec 14, 2005·International Review of Cytology·Esteban M RodríguezPedro Amat
Apr 22, 2006·Journal of Alzheimer's Disease : JAD·Nataniel Lester-CollSuzanne M de la Monte
Sep 22, 2006·Journal of Alzheimer's Disease : JAD·Suzanne M de la MonteJack R Wands
Jan 16, 2007·Neurobiology of Aging·Lisa MosconiMony J de Leon
Oct 3, 2007·The European Journal of Neuroscience·Sachin PatilChristina Chan
May 8, 2008·Current Opinion in Lipidology·Edward W Kraegen, Gregory J Cooney
Jun 30, 2009·Pharmacotherapy·Aaron M CookJimmi Hatton

❮ Previous
Next ❯

Citations

Dec 31, 2016·Translational Research : the Journal of Laboratory and Clinical Medicine·Thomas DiehlDimitrios Kapogiannis
Jan 21, 2017·Journal of Alzheimer's Disease : JAD·Dalton L EbelTim D Ostrowski
Nov 6, 2018·Daru : Journal of Faculty of Pharmacy, Tehran University of Medical Sciences·Molood Alsadat VakilinezhadRassoul Dinarvand
Nov 16, 2018·CNS & Neurological Disorders Drug Targets·Smriti GuptaRajat Sandhir
Aug 12, 2017·Journal of Alzheimer's Disease : JAD·Konstantin BlochAbraham Weizman
Mar 12, 2020·Journal of Basic and Clinical Physiology and Pharmacology·Ravinder KaurRicha Shri
Jul 11, 2018·Nutrients·Kok-Yong Chin, Shu Shen Tay
Feb 26, 2020·Molecular Biology Reports·Isabella Pregardier KlannCristina Wayne Nogueira
May 23, 2018·Disease Models & Mechanisms·Mazen Asaad, Jin Hyung Lee
Aug 21, 2018·Journal of Alzheimer's Disease : JAD·Mariane C VicenteLuciane H Gargaglioni
Aug 11, 2020·Evidence-based Complementary and Alternative Medicine : ECAM·Zhenhong LiuPengwen Wang

❮ Previous
Next ❯

Methods Mentioned

BETA
transgenic

Related Concepts

Related Feeds

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.